X0609 4 2026-03-16 0 0001570562 Evolus, Inc. EOLS 0001432063 Avelar Rui true 520 NEWPORT CENTER DR. SUITE 1200 NEWPORT BEACH 92660 0 1 0 0 See Remarks 1 Common Stock 2026-03-16 4 M 0 8804 0 A 460538 D Common Stock 2026-03-17 4 S 0 29996 4.8883 D 430542 D Performance Restricted Stock Units 2026-03-16 4 M 0 8804 0 D Common Stock 8804 8802 D As previously reported, on February 7, 2024, the Reporting Person was granted 17,606 performance restricted stock units ("PSUs") at target pursuant to the Evolus, Inc. 2017 Omnibus Incentive Plan. The PSUs were subject to performance conditions based on certain pre-specified revenue and defined non-GAAP operating profit measured over the Issuer's 2024 and 2025 fiscal years. The Compensation Committee certified achievement at 100% of target, resulting in 17,606 earned PSUs. Of the earned PSUs, 50% vested and settled on March 16, 2026, resulting in the issuance of 8,804 shares of the Issuer's common stock. The remaining 8,802 PSUs remain outstanding and are scheduled to vest on February 7, 2027, subject to continued service. The number of shares reported reflects rounding adjustments applied in accordance with the terms of the award and administrative procedures. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of multiple PSU and restricted stock unit awards. The shares were sold in multiple trades at prices ranging from $4.8874 to $4.945. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Chief Medical Officer and Head of Research & Development /s/ Jeffrey J. Plumer, as attorney-in-fact for Rui Avelar 2026-03-18